Workflow
宁科生物(600165) - 2023 Q3 - 季度财报
NSWRCNSWRC(SH:600165)2023-10-27 16:00

Financial Performance - The company's operating revenue for Q3 2023 was ¥66,620,576.29, a decrease of 49.08% compared to the same period last year[4]. - The net profit attributable to shareholders for the year-to-date period was -¥220,224,822.32, reflecting a decline of 72.18% year-on-year[4]. - The basic and diluted earnings per share for Q3 2023 were both -¥0.122, with a year-to-date figure of -¥0.322[5]. - The net profit for Q3 2023 was -247,882,375.55 RMB, compared to -29,776,569.32 RMB in Q3 2022, indicating a significant decline in profitability[20]. - The total revenue from operating activities was 155,827,411.44 RMB in Q3 2023, down from 707,025,408.18 RMB in Q3 2022, reflecting a decrease of approximately 78%[23]. - The company reported a total comprehensive income of -247,851,414.30 RMB for Q3 2023, compared to -29,473,330.06 RMB in Q3 2022[21]. - Basic and diluted earnings per share for Q3 2023 were both -0.322 RMB, compared to -0.031 RMB in Q3 2022, indicating a worsening performance per share[21]. - The total financial expenses for Q3 2023 were 99,698,875.24 RMB, up from 49,794,319.02 RMB in Q3 2022, representing an increase of approximately 100%[20]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was -¥30,519,828.13, representing a decline of 125.70%[5]. - The operating cash flow for Q3 2023 was -30,519,828.13 RMB, compared to a positive cash flow of 118,752,400.73 RMB in Q3 2022[23]. - Cash and cash equivalents at the end of Q3 2023 were 9,332,768.60 RMB, down from 12,241,217.59 RMB at the end of Q3 2022, showing a decrease of about 24%[24]. - The net cash flow from financing activities for Q3 2023 was 12,481,687.62 RMB, a recovery from a negative cash flow of -106,754,389.14 RMB in Q3 2022[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,136,576,468.24, down 4.33% from the end of the previous year[5]. - Total liabilities as of September 30, 2023, were CNY 2,490,346,797.69, an increase from CNY 2,384,616,750.65 at the end of 2022, representing an increase of approximately 4.4%[16]. - The company's total current assets decreased to CNY 171,992,076.20 from CNY 251,858,363.07, a decline of about 31.6%[14]. - The company's total non-current assets were CNY 2,964,584,392.04, down from CNY 3,026,839,472.43, indicating a decrease of approximately 2.1%[14]. - The company's total equity decreased to CNY 646,229,670.55 from CNY 894,081,084.85, a decline of about 27.8%[16]. - Short-term borrowings increased to CNY 346,792,963.39 from CNY 331,340,167.81, reflecting an increase of approximately 4.4%[15]. - The company reported a net loss of CNY 749,441,968.03 in retained earnings as of September 30, 2023, compared to a loss of CNY 529,217,145.71 at the end of 2022[16]. Operational Highlights - The company reported a significant reduction in sales volume, primarily due to decreased demand for its products[9]. - Total revenue for the first three quarters of 2023 was CNY 168,608,929.26, a significant decrease from CNY 606,123,354.86 in the same period of 2022, representing a decline of approximately 72.1%[19]. - Total operating costs for the first three quarters of 2023 amounted to CNY 397,869,702.37, down from CNY 659,034,504.41 in 2022, indicating a reduction of about 39.6%[19]. - Research and development expenses for the first three quarters of 2023 were CNY 9,839,240.66, compared to CNY 22,767,555.43 in 2022, reflecting a decrease of approximately 56.6%[19]. - The company received government subsidies amounting to ¥390,155.55 during the reporting period, which are related to its normal business operations[7]. - The company has not disclosed any new product developments or market expansion strategies in this report[9]. Impairment and Losses - Non-recurring gains and losses for the year-to-date period totaled -¥7,999,868.08, with a tax impact of -¥3,167,550.80[8]. - The company incurred an asset impairment loss of -25,028,787.09 RMB in Q3 2023, contrasting with a gain of 5,033,130.80 RMB in Q3 2022[20].